PepGen Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before August 8, 2025 to Discuss Your Rights - PEPG

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of PepGen Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its lead product candidate, PGN-EDO51, and its clinical study, CONNECT2 [1][2]. Allegations - The lawsuit claims that during the class period from March 7, 2024, to March 3, 2025, PepGen misrepresented the effectiveness and safety of PGN-EDO51 [1]. - It is alleged that the CONNECT2 study was dangerous or deficient for FDA approval, leading to the likelihood of halting the study [1]. - The complaint states that the clinical, regulatory, and commercial prospects of PGN-EDO51 were overstated, making the company's public statements materially false and misleading [1]. Class Action Details - Shareholders who purchased shares of PepGen during the specified class period are encouraged to register for the class action by August 8, 2025 [2]. - Registration allows shareholders to receive updates on the case and does not incur any costs or obligations [2]. Law Firm Background - The Gross Law Firm is recognized for its commitment to protecting investors' rights against deceit and fraud, aiming to hold companies accountable for misleading practices [3].